Authorisation status
Authorised by all European Union countries through their national authorisation procedures. The prescribing information has been harmonised across all of these countries.
Summary information
Relenza is an antiviral medicine that contains the active substance zanamivir. It has been authorised individually by all 27 EU Member States through the mutual-recognition procedure, coordinated by the Medical Products Agency in Sweden.
Further information on Relenza is available in the following documents, published by the Medical Products Agency in Sweden: